Oncobiologics Rebrands And Brings In Staff To Push Through Candidate

 
• By Dean Rudge

  All change for Oncobiologics as it becomes Outlook Therapeutics, names chief commercial and chief operating officers and collects US$4 million. The New Jersey-based player is solely focused on a novel bevacizumab intravitreal formulation for wet AMD and other retina diseases.

Waves
IT'S A NEW DAWN FOR ONCOBIOLOGICS • Source: Shutterstock

More from Biosimilars

More from Products